Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23080563 | 0.92 | MDM2 (0.48) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL28982175 | 0.92 | MDM2 (0.48) | MDM2MDM4TP53CASP3SYK | |
| SCHEMBL30385583 | 0.92 | MDM2 (0.48) | MDM2MDM4TP53CASP3SYK | |
| SCHEMBL28982176 | 0.92 | MDM2 (0.48) | MDM2MDM4TP53CASP3SYK | |
| SCHEMBL30403561 | 0.92 | MDM2 (0.48) | MDM2MDM4TP53CASP3SYK | |
| SCHEMBL29598621 | 0.89 | MDM2 (0.45) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL5631124 | 0.88 | KMT2A (0.47) | MDM2MDM4TP53KMT2A | |
| SCHEMBL5631131 | 0.88 | KMT2A (0.47) | MDM2MDM4TP53KMT2A | |
| SCHEMBL30385844 | 0.87 | KMT2A (0.46) | MDM2MDM4TP53CASP3KMT2A | |
| SCHEMBL30385972 | 0.86 | MDM2 (0.45) | MDM2MDM4TP53CASP3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-25 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-05-11 | — | — | US | disclosed |
| WO-2021127460-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MDM2 4458/4885MDM4 4763/4885TP53 4077/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MDM2 4458/4885MDM4 4763/4885TP53 4077/4885 |
| US-20230159592-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MDM2 4549/4885MDM4 4743/4885TP53 4401/4885 |
| US-20230144324-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | MDM2 3791/4885MDM4 4772/4885TP53 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.